Processa Pharmaceuticals Stock Performance
Shares of PCSA stock opened at $0.42 on Friday. The stock has a market cap of $10.46 million, a price-to-earnings ratio of -0.37 and a beta of 0.11. Processa Pharmaceuticals has a 52-week low of $0.18 and a 52-week high of $2.24. The firm’s 50-day moving average is $0.34 and its 200-day moving average is $0.44.
Institutional Inflows and Outflows
Processa Pharmaceuticals Company Profile
Processa Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on developing the chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.
- Five stocks we like better than Processa Pharmaceuticals
- Investing in Vaccines 101: How to Invest in Vaccine Stocks
- The most upgraded stocks in November have two things in common
- How to Invest in Semiconductors
- Monday.com rocked earnings like it’s the weekend
- Large Cap Stock Definition and How to Invest
- Plan to own one retailer? Make it this one
Receive News & Ratings for Processa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Processa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.